MNKD
MannKind Corporation · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 92 | 0 | 123.03M | $523.50M | +9 | −9 |
| Q1 2026 | 95 | -6 | 143.26M | $351.80M | +6 | −12 |
| Q4 2025 | 99 | +3 | 133.27M | $755.65M | +3 | — |
| Q3 2025 | 17 | -2 | 89.45M | $480.37M | +1 | −3 |
| Q2 2025 | 16 | 0 | 83.27M | $311.43M | — | — |
| Q1 2025 | 13 | 0 | 35.19M | $177.04M | — | — |
| Q4 2024 | 13 | 0 | 35.66M | $229.30M | — | — |
| Q3 2024 | 12 | +1 | 19.40M | $122.05M | +1 | — |
| Q2 2024 | 11 | — | 20.14M | $105.14M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 6.31M | — | $32.97M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 2 | Millennium Management ✦ | 4.74M | — | $24.77M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | D. E. Shaw & Co. ✦ | 2.88M | — | $15.06M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Two Sigma Investments ✦ | 2.82M | — | $14.74M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 1.70M | — | $8.89M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 6 | Wellington Management ✦ | 779.32K | — | $4.07M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 7 | Marshall Wace ✦ | 599.36K | — | $3.13M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 8 | T. Rowe Price ✦ | 190.66K | — | $996,000 | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Gotham Asset Management ✦ | 42.78K | — | $223,301 | 0.0% | n/c | 1 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 42.73K | — | $223,050 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 11 | Renaissance Technologies ✦ | 12.74K | — | $66,529 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 250 holders, 176.45M shares, $430.71M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 39.05K sh · $128,478
Director · 33.56K sh · $127,856
Director · 39.05K sh · $158,547
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology